Latest MSD News & Updates

See the latest news and media coverage for MSD. We track all announcements, press releases, and industry mentions in real time, all in one place.

MSD

Research-intensive biopharmaceutical company

msd.com

Headquarters: Rahway, United States
Company type: Public company
Number of employees: 35,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about MSD

In short: MSD reported $16.3 billion in Q1 sales and advanced its pipeline with key FDA approvals, major AI partnerships, and strategic acquisitions.

Company announcements

July 22 MSD

MSD announces positive Phase 3 trial results for once-weekly HIV treatment

The ISL/LEN regimen showed noninferiority to daily oral standard of care at 48 weeks in two trials.

July 1 MSD

MSD is advancing its largest pipeline with AI

It leverages AI and data science to accelerate drug discovery for new patient solutions.

June 22 MSD

MSD's tulisokibart met Phase 3 UC trial endpoints

The anti-TL1A antibody achieved clinical remission at 12 weeks in patients with moderately to severely active ulcerative colitis, with no safety concerns identified.

May 8 MSD

MSD states no material impact from Daiichi Sankyo's manufacturing update

MSD remains confident in their ADC collaboration's multibillion-dollar opportunity. Daiichi Sankyo handles manufacturing for most ADCs; MSD for gocatamig.

Media coverage

July 24 Yahoo

Battle rages over access to new ‘miracle’ HIV drug

For the first time in the four-decade fight against HIV there is a “miracle” drug that can all but eliminate the risk of infection, but...

July 22 JUVE Patent

The Hague dismisses Halozyme's PI bid against MSD over Keytruda

The District Court The Hague rejects Halozyme's PI bid seeking to bar MSD marketing the subcutaneous version of cancer drug Keytruda...

July 21 Morningstar

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and...

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy – High Rates of...

July 20 Pharmaphorum

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with...

Never miss news about MSD

Track MSD and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

MSD competitors & trending companies

Browse news for competitors to MSD and other trending companies.